Simplify Logo

Full-Time

Buyer Planner

Posted on 7/23/2024

Quanterix

Quanterix

201-500 employees

Ultra-sensitive biomarker detection technology

Biotechnology
Healthcare

Mid

Billerica, MA, USA

Requires 100% on-site presence in Billerica, MA.

Category
Supply Chain Management
Operations & Logistics
Requirements
  • 2-5 years of experience in supply chain
Responsibilities
  • Purchasing across multiple product types
  • Analyzing historical material usage and annual forecast usage
  • Performing procurement activities
  • Working cross functionally with planning, quality control, and manufacturing
  • Monitoring open purchase order report
  • Managing requests from QC-Incoming and Receiving
  • Managing and maintaining supplier performance report
  • Working cross functionally with internal stakeholders
  • Continuously monitoring and adjusting safety stock levels
  • Reviewing invoices and resolving supplier invoicing issues
  • Managing New Vendors and request for adding to the Approved Vendor list

Quanterix focuses on ultra-sensitive biomarker detection for early disease detection and monitoring in biotechnology and healthcare. Their key technology, Simoa (Single Molecule Array), allows for the detection of biomarkers at very low levels, which is crucial for identifying diseases before symptoms appear. Quanterix differentiates itself by providing advanced imaging systems and tailored assay development services, enabling clients to achieve more accurate results. The company's goal is to empower early disease detection, ultimately improving patient outcomes.

Company Stage

IPO

Total Funding

$559.6M

Headquarters

Lexington, Kentucky

Founded

2007

Growth & Insights
Headcount

6 month growth

3%

1 year growth

11%

2 year growth

18%
Simplify Jobs

Simplify's Take

What believers are saying

  • The FDA's Breakthrough Device designation for Quanterix's p-Tau 217 blood test highlights its potential to revolutionize Alzheimer's disease diagnosis.
  • Partnerships with leading health networks like Mayo Clinic and Mass General Brigham expand Quanterix's reach and impact in clinical diagnostics.
  • Continuous innovation, such as the introduction of the Simoa Advantage PLUS platform, ensures Quanterix remains at the forefront of biomarker research.

What critics are saying

  • The highly competitive biotechnology sector requires Quanterix to continuously innovate to maintain its market position.
  • Dependence on partnerships and collaborations may pose risks if these relationships falter or fail to deliver expected outcomes.

What makes Quanterix unique

  • Quanterix's Simoa technology allows for ultra-sensitive biomarker detection, setting it apart from competitors in early disease detection.
  • The company's focus on non-invasive blood-based biomarker tests for diseases like Alzheimer's provides a significant advantage over traditional, more invasive methods.
  • Quanterix's extensive patent portfolio, including over thirty U.S. patents, underscores its innovative edge in the biotechnology and healthcare markets.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE